Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety of Sirolimus for Treating Lymphangioleiomyomatosis (LAM)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by Office of Rare Diseases (ORD).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Information provided by:
Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier:
NCT00414648
First received: December 20, 2006
Last updated: August 27, 2009
Last verified: August 2009